

Update Bulletin

OCTOBER 2018

The changes in this bulletin apply to all groups that use the PAI Preferred Drug List (PDL).

EXCLUDED DRUG LIST

Additions

These drugs will be added to the Excluded Drug List, effective January 1, 2019. Letters will be sent to affected members around November 1.

- fenoprofen (generic)
- Lazanda
- Levorphanol
- naprelan (generic)
- Oxtellar XR (only brand excluded; generic is covered)
- Qudexy XR (only brand excluded; generic is covered)
- Remodulin
- Tassigna
- Trokendi XR (only brand excluded; generic is covered)
- Ventavis
- Zolpimist

Removals

These drugs will be removed from the Excluded Drug List and added to the formulary. No letters are required.

Effective Nov. 1, 2018

- Braftovi (non-preferred specialty)
- Mektovi (non-preferred specialty)
- Upravi (preferred)

Effective Jan. 1, 2019

- Biktarvy (preferred)
- Cimduo (preferred)
- Descovy (preferred)
- Odefsey (preferred)
- Ozempic (preferred)
- Symfi/Lo (preferred)
- Vraylar (non-preferred)

PRIOR AUTHORIZATION UPDATES

The **red, bolded** drugs in the middle column will be added to the prior authorization program effective January 1, 2019. Letters will be sent to affected members around November 1.

Condition/Drug Class	Before you have coverage for one of these drugs...	...you must have tried one (or more) of these alternative drugs first.
Diabetes (Insulin)	Novolin Relion	Novo Novolin
Diabetes (DPP-4)	Jentadueto/XR, Kazano, Kombiglyze/XR Nesina, Onglyza , Oseni, Tradjenta,	Januvia, Janumet/XR
Diabetes (GLP-1)	Bydureon/BCISE , Byetta	Ozempic, Trulicity, Victoza

STEP THERAPY UPDATES

The **red, bolded** drugs in the right-hand column will be added to the Step Therapy program effective January 1, 2019. Letters will be sent to affected members around November 1.

Condition/Drug Class	First-Choice Drugs You must try one or more of these drugs first, or your doctor must request an override for you ...	Second-Choice Drugs ... before you can get coverage for these drugs.
Diabetes (GLP-1)	metformin, metformin ER (generic Glucophage XR)	Ozempic, Trulicity, Victoza*
Behavioral Health	TWO of these generics: aripiprazole, clozapine/ODT, olanzapine, paliperidone, quetiapine, quetiapine ext rel, risperidone, ziprasidone	Clozaril, Fanapt, Fazaclo, Geodon, Invega, Latuda, Risperdal, Saphris, Versacloz, Vraylar , Zyprexa

*Ozempic, Trulicity and Victoza are preferred brands

PREFERRED DRUG LIST UPDATES

Cialis

Brand Cialis is moving to non-preferred status due to the availability of a generic alternative (tadalafil), effective January 1, 2019. Letters are not sent for drugs moving tiers due to generic availability.

SPECIALTY DRUG UPDATES

Drugs Moving To Preferred Status (Pharmacy Benefit)

Changes effective January 1, 2019. Drugs will require prior authorization. Letters are not sent about positive tier changes.

- Bosulif
- Erleada
- Ibrance
- Kevzara
- Kisqali
- Opsumit
- Sprycel
- Uptravi
- Xeljanz/XR
- Xtandi
- Zytiga

PREVENTIVE DRUG LIST UPDATE

Beginning January 1, 2019, we will remove several categories of drugs from our standard preventive drug list. These categories will no longer be offered to groups who newly adopt a preventive drug benefit.

Therapeutic Class	Reason for Removal
Allergenic Extracts	Few groups currently select preventive coverage of this category.
Contraceptives	Drugs in category covered at \$0 under ACA
Fluoride Supplements	Drugs in category covered at \$0 under ACA
Immunizing Agents	Drugs in category covered at \$0 under ACA
Tobacco Cessation	Drugs in category covered at \$0 under ACA

For New Groups

Groups will continue to select any combination of drug classes from our Preventive Drug Checklist, which will include the 12 categories listed below. As before, they will be able to select any combination of generic, preferred and non-preferred brand drugs.

- Asthma/COPD
- Asthma Supplies
- Blood Thinners
- Cholesterol
- Depression
- Diabetic Drugs
- Diabetic Supplies
- High Blood Pressure
- Osteoporosis
- Pediatric Vitamins
- Prenatal Vitamins
- Weight Loss

Groups that wish to cover the excluded drug categories can still request them as additional classes.

For Current Groups

Preventive lists for current groups will remain unchanged until each group's rep has a chance to review this information with them and advise whether they should adopt the new standard list. At that time, Pharmacy Management can provide impact to show any disruption that would occur if the group were to change to the new standard list. Pharmacy Management will also work to communicate any preventive benefit changes the group elects with its members.

Please direct questions to your PAI account executive.